Europe LDL test market is expected to grow at a CAGR of 7.6% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Component (Kits & Reagents, Devices, Services), Disease (Diabetes, Stroke, Atherosclerosis, Obesity, Dyslipidemia, Carotid Artery Disease, Peripheral Arterial Disease, Angina, Others), Distribution Channel (Direct Tenders, Retail), End User (Hospitals, Clinics, Ambulatory Care, Research Laboratory), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Belgium, Turkey, Rest of Europe)


Major growing sectors under the market segmentation are as follows:


? On the basis of components, kits & reagents segment is dominating the market as it shows the results within less period of time and it is easy to use. The kits & reagents are majorly preferred for diagnosis by the end users.

? On the basis of disease, diabetes segment growing is dominating the market because increasing prevalence of diabetes also raise demand of LDL test to elevate risk of diabetes.

? On the basis of distribution channel, a direct tender is expected to dominate the market due to increasing direct supply of LDL test devices kits and reagents into the hospitals and laboratories.

? On the basis of end user, hospital is expected to dominating the market due to increasing use of LDL test devise and kits and reagents.


Key Market Players


The key market players are listed below:

? Quest Diagnostics
? Sekisui Diagnostics
? Express Biotech International
? Randox Laboratories Ltd
? Reckon diagnostics
? Diasys Diagnostic Systems GmbH
? F. Hoffmann-La Roche Ltd
? Abbott
? Eurolyser Diagnostica GmbH
? Sigma-Aldrich
? Diazyme Laboratories, Inc.
? Laboratory Corporation of America
? Cell Biolabs, Inc.
? Atlas Medical U.K
? Eurofins Scientific
? Thermo Fisher Scientific Inc.
? Home Access Health